 Athira Pharma Inc NASDAQ: ATHA shares are falling to 52-week lows after announcing disappointing topline results from its exploratory ACT-AD Phase 2 study of fosgonimeton ATH-1017 in mild-to-moderate Alzheimers disease AD. The study did not meet the primary endpoint. 